SCHEMBL759728

SCHEMBL759728

O=C(Cl)c1ccc(F)c(C(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNQ3 O43525 2/20 0.54
KCNQ2 O43526 2/20 0.54
KCNE1 P15382 2/20 0.54
KCNQ1 P51787 2/20 0.54
TAS1R3 Q7RTX0 2/20 0.49
TAS1R1 Q7RTX1 2/20 0.49
TAS1R2 Q8TE23 2/20 0.49
HDAC8 Q9BY41 1/20 0.45
VNN1 O95497 6/20 0.44
KIF11 P52732 1/20 0.44
GRM4 Q14833 1/20 0.43
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
RAB9A P51151 1/20 0.41
AR P10275 2/20 0.41
KMO O15229 1/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30308280 0.85 KIF11 (0.56) KCNQ3KCNQ2KCNE1KCNQ1KIF11
SCHEMBL662965 0.85 KIF11 (0.56) KCNQ3KCNQ2KCNE1KCNQ1KIF11
SCHEMBL10659911 0.84 VNN1 (0.56) KCNQ3KCNQ2KCNE1KCNQ1TAS1R3
SCHEMBL31542017 0.84 NOTUM (0.42) KCNQ3KCNQ2KCNE1KCNQ1HDAC8
SCHEMBL2680326 0.84 NOTUM (0.42) KCNQ3KCNQ2KCNE1KCNQ1HDAC8
SCHEMBL31438988 0.82 TAS1R3 (0.54) KCNQ3KCNQ2KCNE1KCNQ1TAS1R3
SCHEMBL30892335 0.82 GLA (0.45) KCNQ3KCNQ2KCNE1KCNQ1KIF11
SCHEMBL278277 0.82 GLA (0.45) KCNQ3KCNQ2KCNE1KCNQ1KIF11
SCHEMBL78878 0.82 TAS1R3 (0.54) KCNQ3KCNQ2KCNE1KCNQ1TAS1R3
SCHEMBL14012598 0.81 KIF11 (0.60) KCNQ3KCNQ2KCNE1KCNQ1TAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 290 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025090928-A9 COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES AQUINNAH PHARMACEUTICALS, INC. (US) 2026-04-30 WO disclosed
US-20260034252-A1 FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF RATIO THERAPEUTICS INC (US) 2026-02-05 US disclosed
EP-4441052-B1 COMPOUNDS FUNDACION DEL SECTOR PUBLICO ESTATAL CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III F S P CNIO (ES) 2025-11-19 EP disclosed
EP-4561998-A1 FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF Ratio Therapeutics, Inc. (US) 2025-06-04 EP disclosed
WO-2025090928-A1 COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES AQUINNAH PHARMACEUTICALS, INC. (US) 2025-05-01 WO disclosed
US-20250051293-A1 NOVEL OXADIAZOLE DERIVATIVE AND USE THEREOF CELROS BIOTECH (KR) 2025-02-13 US disclosed
US-20250042918-A1 COMPOUNDS Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P.CNIO) (ES) 2025-02-06 US disclosed
EP-4441052-A1 COMPOUNDS Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) 2024-10-09 EP disclosed
CN-118695762-A Preparation method of composite material, light-emitting device and electronic equipment TCL科技集团股份有限公司 2024-09-24 CN disclosed
EP-4431498-A1 NOVEL OXADIAZOLE DERIVATIVE AND USE THEREOF Celros Biotech (KR) 2024-09-18 EP disclosed
EP-0863755-A1 ANTITHROMBOTIC DIAMINES ELI LILLY AND COMPANY (US) 1998-09-16 EP disclosed
WO-1998008839-A1 COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED THIOPHENE LIBRARIES ELI LILLY AND COMPANY (US) 1998-03-05 WO disclosed
EP-0824917-A2 Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis ELI LILLY AND COMPANY (US) 1998-02-25 EP disclosed
EP-0825164-A2 Scavenger assisted combinatorial process for preparing libraries of amides, carbamates and sulfonamides ELI LILLY AND COMPANY (US) 1998-02-25 EP disclosed
WO-1998006402-A1 TREATMENT OF THE COMMON COLD OR ALLERGIC RHINITIS ELI LILLY AND COMPANY (US) 1998-02-19 WO disclosed
WO-1997026300-A1 COMBINATORIAL PROCESS FOR PREPARING SUBSTITUTED INDANE LIBRARIES ELI LILLY AND COMPANY (US) 1997-07-24 WO disclosed
WO-1997025033-A1 ANTITHROMBOTIC DIAMINES ELI LILLY AND COMPANY (US) 1997-07-17 WO disclosed
WO-1997013512-A1 N-[2-SUBSTITUTED-3-(2-AMINOETHYL)-1H-INDOL-5-YL]-AMIDES: NEW 5-HT1F AGONISTS ELI LILLY AND COMPANY (US) 1997-04-17 WO disclosed
EP-0768301-A1 N-(2-substituted-3-(2-aminoethyl)-1H-indol-5-yl)-amides as new 5-HT1F agonists ELI LILLY AND COMPANY (US) 1997-04-16 EP disclosed
EP-0640587-A1 Diacyl substituted guanidins, process for their preparation, their use as medicament or diagnostic reagent and medicament containing them HOECHST AKTIENGESELLSCHAFT (DE) 1995-03-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051293-A1 NOVEL OXADIAZOLE DERIVATIVE AND USE THEREOF NOX1, NOX3, NOX4 KCNQ3 3880/4885KCNQ2 4035/4885KCNE1 3786/4885
US-20260034252-A1 FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF CCR6, OGFRL1, IL6ST KCNQ3 4772/4885KCNQ2 4790/4885KCNE1 4710/4885
US-20250042918-A1 COMPOUNDS PIM1, PIM3, PIM2 KCNQ3 1138/4885KCNQ2 1523/4885KCNE1 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.